Literature DB >> 21696255

Performance and clinical significance of direct antimicrobial susceptibility testing on urine from hospitalized patients.

Karlijn B Klein Breteler1, Rob J Rentenaar, Gemma Verkaart, Patrick D J Sturm.   

Abstract

BACKGROUND: Urinary tract infections (UTIs) are common infections in the community and the hospital. With increasing antimicrobial resistance, specifically in the Gram-negative uropathogens, reliable, rapid antimicrobial susceptibility data would be useful to guide antimicrobial treatment. Direct antimicrobial susceptibility testing (DST) of urine with microscopic evidence of Gram-negative bacterial infection and its clinical significance was investigated in this study.
METHODS: DST was performed by Kirby-Bauer disk diffusion method using undiluted urine as a non-standardized inoculum. Urine specimens with Gram-negative bacteria on microscopy were included. DST results from growth of Gram-negative bacteria were compared to routine antimicrobial susceptibility testing by Phoenix automated system (AST). Errors were scored as 'very major error' if susceptible by DST but resistant by AST and as 'major error' if resistant by DST but susceptible by AST. All other discrepancies were defined as 'minor error'. Discrepancies were resolved by determination of minimum inhibitory concentrations (MICs) using Etests. After discrepancy analysis, errors were scored as above using the Etest as the reference method. For analysis, specimens were divided into 3 categories: category A: 1 isolate found by DST as well as by routine culture; category B: 1 isolate detected by DST, but more than 1 isolate found on routine culture; category C: more than 1 isolate found by both DST and routine culture. The clinical significance of DST was determined prospectively by investigating the potential impact of DST on antimicrobial therapy.
RESULTS: One hundred and sixteen urine specimens were included. For DST and AST there was agreement in 96% of 1152 comparisons in category A (n = 100), 88% of 41 comparisons in category B (n = 4), and 88% of 110 comparisons in category C (n = 12). The 64 discrepancies included 18 very major errors, 7 major errors, and 39 minor errors. Eight very major errors and 11 minor errors were not investigated because the isolates were not available. After Etest MIC determination for the 45 remaining discrepancies, DST showed 1 very major error, 1 major error, and 8 minor errors in category A, none in category B, and 5 major errors and 4 minor errors in category C. Antimicrobial therapy for UTI was prescribed for 53 patients. For 4 patients (8%) therapy was adjusted based on DST because of antimicrobial resistance and for 12 patients (23%) antimicrobial treatment could have been streamlined.
CONCLUSIONS: DST on urine is reliable in monobacterial Gram-negative infections. With increasing antimicrobial resistance, DST can make an important contribution to patient management and reduce the use of broad-spectrum antimicrobials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21696255     DOI: 10.3109/00365548.2011.588609

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  Oral doxycycline for non-systemic urinary tract infections (UTIs) due to P. aeruginosa and other Gram negative uropathogens.

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-06       Impact factor: 3.267

2.  An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH.

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-09       Impact factor: 3.267

3.  Rapid Identification of Klebsiella pneumoniae by Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry and Detection of Meropenem Resistance by Flow Cytometric Assay.

Authors:  Abdullah Kilic; Eyup Dogan; Sinem Kaya; Sema Oren; Duran Tok; Nurittin Ardic; Mehmet Baysallar
Journal:  J Clin Lab Anal       Date:  2016-05-30       Impact factor: 2.352

4.  Direct Urine Resistance Detection Using VITEK 2.

Authors:  Eva Torres-Sangiao; Brais Lamas Rodriguez; María Cea Pájaro; Raquel Carracedo Montero; Noelia Parajó Pazos; Carlos García-Riestra
Journal:  Antibiotics (Basel)       Date:  2022-05-15

5.  Direct susceptibility testing by disk diffusion on clinical samples: a rapid and accurate tool for antibiotic stewardship.

Authors:  L Coorevits; J Boelens; G Claeys
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-20       Impact factor: 3.267

Review 6.  Use of rapid diagnostic techniques in ICU patients with infections.

Authors:  Almudena Burillo; Emilio Bouza
Journal:  BMC Infect Dis       Date:  2014-11-28       Impact factor: 3.090

7.  Direct disk testing versus isolation and antimicrobial susceptibility testing of urine from urinary tract infection.

Authors:  Raz Nawzad Mohammad; Sherko Ali Omer
Journal:  Iran J Microbiol       Date:  2018-02

Review 8.  Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.

Authors:  Derry K Mercer; Marcelo D T Torres; Searle S Duay; Emma Lovie; Laura Simpson; Maren von Köckritz-Blickwede; Cesar de la Fuente-Nunez; Deborah A O'Neil; Alfredo M Angeles-Boza
Journal:  Front Cell Infect Microbiol       Date:  2020-07-07       Impact factor: 5.293

9.  Rapid detection of tetracycline resistance in bovine Pasteurella multocida isolates by MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA).

Authors:  Laura Van Driessche; Jade Bokma; Linde Gille; Pieter-Jan Ceyssens; Katrin Sparbier; Freddy Haesebrouck; Piet Deprez; Filip Boyen; Bart Pardon
Journal:  Sci Rep       Date:  2018-09-11       Impact factor: 4.379

10.  Direct identification and susceptibility testing of Gram-negative bacilli from turbid urine samples using VITEK2.

Authors:  Neelima Angaali; Laxmi Vemu; Chavali Padmasri; Neeraja Mamidi; Vijay Dharma Teja
Journal:  J Lab Physicians       Date:  2018 Jul-Sep
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.